Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide for Adult Brainstem Glioma
NCT03932981Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in brainstem glioma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
temozolomide
03
Conditions
brainstem glioma
Beyond the preview
Go deeper on NCT03932981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932981.